Lakefront Biotherapeutics (LKFT) Other Non-Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Other Non-Current Liabilities for 13 consecutive years, with $16.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 43.33% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (down 43.33% YoY), while the FY2025 annual figure was $14.7 million, down 59.41% from the prior year.
• Other Non-Current Liabilities grew to $16.1 million in Q1 2026 per LKFT's latest filing, from $14.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $46.6 million in Q1 2024 and bottomed at $10.7 million in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $27.3 million across 5 years, with a median of $28.3 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 172.59% — and 2025, when it tumbled 59.41%.
• Lakefront Biotherapeutics' Other Non-Current Liabilities stood at $22.2 million in 2022, then surged by 52.67% to $34.0 million in 2023, then climbed by 6.4% to $36.1 million in 2024, then sank by 59.41% to $14.7 million in 2025, then grew by 10.03% to $16.1 million in 2026.
• Business Quant data shows LKFT's Other Non-Current Liabilities at $16.1 million in Q1 2026, $14.7 million in Q4 2025, and $28.3 million in Q3 2025.